Cardioprotection through autophagy: Ready for clinical trial?

Autophagy

Volumn 7, Issue 4, 2011, Pages 434-435

  Gottlieb, Roberta A ^a,b   Mentzer Jr , Robert M ^a,b,c  

^a Radical Therapeutix Inc   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Autophagy; Cardioprotection; Chloramphenicol; Ischemia reperfusion injury; Myocardial infarction; Myocardial ischemia

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; BECLIN 1; CHLORAMPHENICOL HEMISUCCINATE; CHLOROCYCLOPENTYLADENOSINE; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN; PROTEIN LC3 II; SULFAPHENAZOLE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; APLASTIC ANEMIA; AUTOPHAGY; BLEEDING; BRAIN HEMORRHAGE; COMORBIDITY; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; LEFT ANTERIOR DESCENDING CORONARY ARTERY; METABOLIC SYNDROME X; NONHUMAN; REPERFUSION INJURY; RHABDOMYOLYSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALIA; SUS;

EID: 79953650957     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.7.4.14442     Document Type: Short Survey

References (0)